FDA Issues Final Guidance on Post-Complete Response Letter Meetings

Drug Industry Daily
A A
The FDA Monday finalized its guidance on post-complete response letter meetings with ANDA applicants, spelling out the criteria for granting or denying meeting requests.

To View This Article:

Login

Subscribe To Drug Industry Daily